No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsManagement of HIV/AIDS in older patients-drug/drug interactions and adherence to antiretroviral therapyHIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future researchHIV infection and cardiovascular diseaseA Review of Management of Inflammation in the HIV PopulationCardiovascular Complications of HIV-Associated Immune DysfunctionWhy the communicable/non-communicable disease dichotomy is problematic for public health control strategies: implications of multimorbidity for health systems in an era of health transitionA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsCardiovascular Complications of HIV Infection.Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.What's new for antiretroviral treatment in women with HIVEvaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?PharmGKB summary: abacavir pathwayRisks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Neurological and psychiatric adverse effects of antiretroviral drugs.Antiretroviral therapy: current drugsEffects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted studySafety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in JapanSafety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in JapanRisk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewSoluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study.Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapyEpidemiology and management of antiretroviral-associated cardiovascular disease.Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial.Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population.SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.Pathophysiology and management of cardiovascular disease in patients with HIVInflammatory Markers Associated With Subclinical Coronary Artery Disease: The Multicenter AIDS Cohort Study.A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV.Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot StudyCardiovascular disease and HIV infection.Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.Cardiovascular involvements in HIV-infected patients.HIV and the heart: the impact of antiretroviral therapy: a global perspective.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.
P2860
Q21999480-3E534C13-8C7C-47BE-A255-E5BDA1E16616Q26768591-7690052F-0CD3-4CA8-84F5-E14457FDD29DQ26775832-121CD1B7-5F51-4C86-8B58-9FDB0FD5092FQ26827746-DED4D64A-79A1-4D91-91E4-2F98F27DB928Q27008915-10073932-5F09-48F7-AB6C-678F24197DA6Q28078962-B522980B-9D14-4515-ADD8-BDFAFB70DA3EQ28084981-A56D8741-C5E7-41C2-AEB1-02D892BF4D52Q28393479-6DC847AC-3562-40AC-B6E0-4E250045D9D8Q28543212-C0153187-339E-4800-8602-10699C0DFC31Q30235920-718B250F-CE56-4859-9679-D7CEF34831B6Q30248286-56A5991C-8A8C-4FA9-A183-BA1E885BCA83Q30391322-B608F4B6-5244-4607-A805-23347B6C6026Q31118978-29B4C23D-05BF-4CB9-A696-2F83539C5FD9Q33649200-31E339CE-80D5-4431-89EB-AC7892873C2DQ33819062-A7505BC4-20FF-46D1-88E2-CBE7DCF1F481Q33841718-C7E509A3-ABFB-482C-82CF-88F217629D94Q34039419-778A7D8A-3B48-4CE4-8924-080B28020813Q34085926-AB266F13-2997-4360-8875-D5851FBE4A30Q34157856-1532128A-7826-47D5-8E8E-C3F4FEA5E058Q34477917-91CEDF87-C481-4F39-A775-C49061421AA9Q34503452-6923AC65-E4E1-498D-86FA-F3CFE02C3454Q34503521-AB7C2F08-7D91-427C-AE69-2A70296A3463Q34651525-58745B2B-4B3A-4C3C-9B2A-373E5A2AF562Q34732822-661D0489-E64E-40DA-9550-5178576F9CFDQ35190397-F6F7031F-A40F-44B6-A4B6-F3B7B6BA8C6EQ35338096-E6A477B4-7E1A-408D-AF3E-B14704925B11Q35970578-946A2ACF-4888-4A30-B085-B9A63C61C2F5Q35977313-903108EB-3512-47EF-9E8C-C66A82F34EB5Q36693929-875EF4F5-60C7-41AB-8E0C-567332795A68Q36811227-7FCA06FA-5E98-4155-A26F-5BE4215E5FD2Q37038775-3552888B-FAC6-44C1-AF4B-FD2D5C58F80DQ37076185-F3525D91-8778-4045-8D64-80C255F60E02Q37196037-3BD5A630-4E18-4A19-8D0A-F649FA244308Q37250180-85BE0CF1-CEDA-4ED2-90AA-3407A2B5067DQ37661603-E009D53F-926B-4968-BA37-57D58AA4451BQ38108736-12A0CE85-0B6A-4F2E-ADAA-E089B749F404Q38131061-BD8DE0B6-F8C0-40C2-A156-C390F06A7DF6Q38152708-23680894-C1EC-4B99-8ACB-7506403F665EQ38172305-6FE97393-2CF8-49A2-8F17-BB96DA3E736AQ38177684-F115C8F9-B474-4E13-9DB4-FA6595460777
P2860
No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
No association of abacavir use ...... dings of an FDA meta-analysis.
@ast
No association of abacavir use ...... dings of an FDA meta-analysis.
@en
No association of abacavir use ...... dings of an FDA meta-analysis.
@nl
type
label
No association of abacavir use ...... dings of an FDA meta-analysis.
@ast
No association of abacavir use ...... dings of an FDA meta-analysis.
@en
No association of abacavir use ...... dings of an FDA meta-analysis.
@nl
prefLabel
No association of abacavir use ...... dings of an FDA meta-analysis.
@ast
No association of abacavir use ...... dings of an FDA meta-analysis.
@en
No association of abacavir use ...... dings of an FDA meta-analysis.
@nl
P2093
P1476
No association of abacavir use ...... dings of an FDA meta-analysis.
@en
P2093
Charles Cooper
Cynthia Kornegay
Eugenio Andraca-Carrera
Kendall A Marcus
Mat Soukup
Peter Miele
P304
P356
10.1097/QAI.0B013E31826F993C
P407
P577
2012-12-01T00:00:00Z